Immunotoxins are composed of:
Immunotoxins chimeric proteins integrating targeting domain derived monoclonal antibody and cytotoxic domain protein toxin to achieve picomolar potency against malignant cells expressing defined surface antigen. Antibody moiety typically Fab prime 50 kDa scFv 25 kDa composed heavy variable light variable domains connected glycine serine linker disulfide-stabilized Fv dsFv recognizing tumor antigens CD22 135 kDa hairy cell leukemia CD25 IL-2 receptor alpha cutaneous T-cell lymphoma mesothelin 40 kDa GPI-anchored mesothelioma pancreatic adenocarcinoma HER2 with affinity 1-10 nM. Toxin component
Ref: Pastan Annu Rev Med 2007 Immunotoxin Construction Principles Review; FDA Lumoxiti Moxetumomab Design Label; Janeway Immunotoxin Antibody Toxin Fusion Mechanism.